Multiple myeloma is a malignancy of terminally differentiated plasma cells, and patients typically present with bone marrow infiltration of clonal plasma cells and monoclonal protein in the serum and/or urine. The diagnosis of multiple myeloma is made when clear end-organ damage attributable to the plasma cell proliferative disorder or when findings that suggest a high likelihood of their development are present. Distinguishing symptomatic multiple myeloma that requires treatment from the precursor stages of monoclonal gammopathy of undetermined significance and smouldering multiple myeloma is important, as observation is the standard for those conditions. Much progress has been made over the past decade in the understanding of disease biology and individualized treatment approaches. Several new classes of drugs, such as proteasome inhibitors and immunomodulatory drugs, have joined the traditional armamentarium (corticosteroids, alkylating agents and anthracyclines) and, along with high-dose therapy and autologous haemopoietic stem cell transplantation, have led to deeper and durable clinical responses. Indeed, an increasing proportion of patients are achieving lasting remissions, raising the possibility of cure for this disease. Success will probably depend on using combinations of effective agents and treating patients in the early stages of disease, such as patients with smouldering multiple myeloma.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Scientific Reports Open Access 26 October 2022
Biomarker Research Open Access 13 October 2022
CXCL13 chemokine is a novel player in multiple myeloma osteolytic microenvironment, M2 macrophage polarization, and tumor progression
Journal of Hematology & Oncology Open Access 10 October 2022
Subscribe to Nature+
Get immediate online access to Nature and 55 other Nature journal
Subscribe to Journal
Get full journal access for 1 year
only $79.00 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2016. CA Cancer J. Clin. 66, 7–30 (2016).
Gonsalves, W. I. et al. Prognostic significance of quantifying circillating plasma cells in multiple myeloma. Clin. Lymphoma Myeloma Leuk. 14, S147 (2014).
Drayson, M. et al. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 97, 2900–2902 (2001).
Kyle, R. A. et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin. Proc. 78, 21–33 (2003).
Rajkumar, S. V. et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 15, e538–e548 (2014). This is the current diagnostic criteria for multiple myeloma and related disorders.
Turesson, I., Velez, R., Kristinsson, S. Y. & Landgren, O. Patterns of multiple myeloma during the past 5 decades: stable incidence rates for all age groups in the population but rapidly changing age distribution in the clinic. Mayo Clin. Proc. 85, 225–230 (2010).
Landgren, O. et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 113, 5412–5417 (2009).
Kyle, R. A. et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N. Engl. J. Med. 346, 564–569 (2002). This is the first large epidemiological study that defined the natural history of MGUS.
Kyle, R. A. et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N. Engl. J. Med. 356, 2582–2590 (2007). This is the first large epidemiological study that defined the natural history of SMM and the risk of progression.
Waxman, A. J. et al. Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood 116, 5501–5506 (2010).
Huang, S. Y. et al. Epidemiology of multiple myeloma in Taiwan: increasing incidence for the past 25 years and higher prevalence of extramedullary myeloma in patients younger than 55 years. Cancer 110, 896–905 (2007).
Kyle, R. A., Nobrega, F. T. & Kurland, L. T. Multiple myeloma in Olmsted County, Minnesota, 1945–1964. Blood 33, 739–745 (1969).
Kyle, R. A. et al. Incidence of multiple myeloma in Olmsted County, Minnesota — trend over 6 decades. Cancer 101, 2667–2674 (2004).
Baris, D. in Neoplastic Diseases of Blood (ed. Wiernik, P. ) 547–563 (Springer, 2013).
Kumar, S. K. et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 28, 1122–1128 (2014). This study demonstrates the improving survival in patients with multiple myeloma.
Ichimaru, M., Ishimaru, T., Mikami, M. & Matsunaga, M. Multiple myeloma among atomic bomb survivors in Hiroshima and Nagasaki, 1950–76: relationship to radiation dose absorbed by marrow. J. Natl Cancer Inst. 69, 323–328 (1982).
Preston, D. L. et al. Cancer incidence in atomic bomb survivors. Part III. Leukemia, lymphoma and multiple myeloma, 1950–1987. Radiat. Res. 137, S68–S97 (1994).
Khuder, S. A. & Mutgi, A. B. Meta-analyses of multiple myeloma and farming. Am. J. Ind. Med. 32, 510–516 (1997).
Burmeister, L. F. Cancer mortality in Iowa farmers, 1971–1978. J. Natl Cancer Inst. 66, 461–464 (1981).
Altekruse, S. F., Henley, S. J. & Thun, M. J. Deaths from hematopoietic and other cancers in relation to permanent hair dye use in a large prospective study (United States). Cancer Causes Control 10, 617–625 (1999).
Bergsagel, D. E. et al. Benzene and multiple myeloma: appraisal of the scientific evidence. Blood 94, 1174–1182 (1999).
Maldonado, J. E. & Kyle, R. A. Familial myeloma. Report of eight families and a study of serum proteins in their relatives. Am. J. Med. 57, 875–884 (1974).
Vachon, C. M. et al. Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance. Blood 114, 785–790 (2009).
Mitchell, J. S. et al. Genome-wide association study identifies multiple susceptibility loci for multiple myeloma. Nat. Commun. 7, 12050 (2016).
Johnson, D. C. et al. Genome-wide association study identifies variation at 6q25.1 associated with survival in multiple myeloma. Nat. Commun. 7, 10290 (2016).
Ziv, E. et al. Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. Nat. Commun. 6, 7539 (2015).
Johnson, D. C. et al. Genetic factors influencing the risk of multiple myeloma bone disease. Leukemia 30, 883–888 (2016).
Magrangeas, F. et al. A genome-wide association study identifies a novel locus for bortezomib-induced peripheral neuropathy in European patients with multiple myeloma. Clin. Cancer Res. 22, 4350–4355 (2016).
Gonzalez, D. et al. Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. Blood 110, 3112–3121 (2007).
Morgan, G. J., Walker, B. A. & Davies, F. E. The genetic architecture of multiple myeloma. Nat. Rev. Cancer 12, 335–348 (2012).
Manier, S., Kawano, Y., Bianchi, G., Roccaro, A. M. & Ghobrial, I. M. Cell autonomous and microenvironmental regulation of tumor progression in precursor states of multiple myeloma. Curr. Opin. Hematol. 23, 426–433 (2016).
Bergsagel, P. L. et al. Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proc. Natl Acad. Sci. USA 93, 13931–13936 (1996).
Bergsagel, P. L. & Kuehl, W. M. Molecular pathogenesis and a consequent classification of multiple myeloma. J. Clin. Oncol. 23, 6333–6338 (2005).
Walker, B. A. et al. Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma. J. Clin. Oncol. 33, 3911–3920 (2015). This is one of the largest studies to show the range of mutations in multiple myeloma.
Hakim, O. et al. DNA damage defines sites of recurrent chromosomal translocations in B lymphocytes. Nature 484, 69–74 (2012).
Avet-Loiseau, H. et al. 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone Myelome. Cancer Res. 59, 4546–4550 (1999).
Ross, F. M. et al. The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance. Haematologica 95, 1221–1225 (2010).
Rajkumar, S. V. et al. Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. Leukemia 27, 1738–1744 (2013).
Chretien, M. L. et al. Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter? Blood 126, 2713–2719 (2015).
Sawyer, J. R. et al. Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma. Leukemia 31, 637–644 (2017).
Gordon, D. J., Resio, B. & Pellman, D. Causes and consequences of aneuploidy in cancer. Nat. Rev. Genet. 13, 189–203 (2012).
Avet-Loiseau, H. et al. Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome experience. J. Clin. Oncol. 31, 2806–2809 (2013).
Bouchard, C. et al. Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27. EMBO J. 18, 5321–5333 (1999).
Chng, W. J. et al. Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma. Leukemia 25, 1026–1035 (2011).
Bolli, N. et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat. Commun. 5, 2997 (2014).
Lohr, J. G. et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell 25, 91–101 (2014).
Rashid, N. U. et al. Differential and limited expression of mutant alleles in multiple myeloma. Blood 124, 3110–3117 (2014).
Keats, J. J. et al. Clonal competition with alternating dominance in multiple myeloma. Blood 120, 1067–1076 (2012).
Weinhold, N. et al. High risk multiple myeloma demonstrates marked spatial genomic heterogeneity between focal lesions and random bone marrow; implications for targeted therapy and treatment resistance. Blood 126, 20 (2015).
Annunziata, C. M. et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12, 115–130 (2007).
Keats, J. J. et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 12, 131–144 (2007).
Cormier, F. et al. Frequent engagement of RelB activation is critical for cell survival in multiple myeloma. PLoS ONE 8, e59127 (2013).
Agirre, X. et al. Whole-epigenome analysis in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers. Genome Res. 25, 478–487 (2015).
Heuck, C. J. et al. Myeloma is characterized by stage-specific alterations in DNA methylation that occur early during myelomagenesis. J. Immunol. 190, 2966–2975 (2013).
Loven, J. et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 153, 320–334 (2013).
Pichiorri, F. et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc. Natl Acad. Sci. USA 105, 12885–12890 (2008).
Galm, O., Yoshikawa, H., Esteller, M., Osieka, R. & Herman, J. G. SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood 101, 2784–2788 (2003).
Puthier, D. et al. Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells. Br. J. Haematol. 107, 392–395 (1999).
Zhao, J. J. et al. miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/beta-catenin/BCL9 pathway. Cancer Res. 74, 1801–1813 (2014).
Tagde, A. et al. MUC1-C drives MYC in multiple myeloma. Blood 127, 2587–2597 (2016).
Cyster, J. G. Homing of antibody secreting cells. Immunol. Rev. 194, 48–60 (2003).
Zhu, D. et al. The cyclophilin A–CD147 complex promotes the proliferation and homing of multiple myeloma cells. Nat. Med. 21, 572–580 (2015).
Ghobrial, I. M. Myeloma as a model for the process of metastasis: implications for therapy. Blood 120, 20–30 (2012).
Roodman, G. D. Mechanisms of bone lesions in multiple myeloma and lymphoma. Cancer 80, 1557–1563 (1997).
Roodman, G. D. Pathogenesis of myeloma bone disease. Leukemia 23, 435–441 (2009).
Damiano, J. S., Cress, A. E., Hazlehurst, L. A., Shtil, A. A. & Dalton, W. S. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 93, 1658–1667 (1999).
McMillin, D. W. et al. Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat. Med. 16, 483–489 (2010).
Roccaro, A. M. et al. BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J. Clin. Invest. 123, 1542–1555 (2013).
Cimmino, A. et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl Acad. Sci. USA 102, 13944–13949 (2005).
Roccaro, A. M. et al. MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood 113, 6669–6680 (2009).
Rajkumar, S. V. et al. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin. Cancer Res. 8, 2210–2216 (2002).
Shaffer, A. L. et al. IRF4 addiction in multiple myeloma. Nature 454, 226–231 (2008).
Kronke, J. et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 343, 301–305 (2014).
Lu, G. et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 343, 305–309 (2014).
Eichner, R. et al. Immunomodulatory drugs disrupt the cereblon–CD147–MCT1 axis to exert antitumor activity and teratogenicity. Nat. Med. 22, 735–743 (2016).
Walters, D. K., Arendt, B. K. & Jelinek, D. F. CD147 regulates the expression of MCT1 and lactate export in multiple myeloma cells. Cell Cycle 12, 3175–3183 (2013).
Gass, J. N., Gifford, N. M. & Brewer, J. W. Activation of an unfolded protein response during differentiation of antibody-secreting B cells. J. Biol. Chem. 277, 49047–49054 (2002).
Aronson, L. I. & Davies, F. E. DangER: protein ovERload. Targeting protein degradation to treat myeloma. Haematologica 97, 1119–1130 (2012).
Leung-Hagesteijn, C. et al. Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell 24, 289–304 (2013).
Abe, M., Harada, T. & Matsumoto, T. Concise review: defining and targeting myeloma stem cell-like cells. Stem Cells 32, 1067–1073 (2014).
Lamy, L. et al. Control of autophagic cell death by caspase-10 in multiple myeloma. Cancer Cell 23, 435–449 (2013).
Goldschmidt, H., Lannert, H., Bommer, J. & Ho, A. D. Multiple myeloma and renal failure. Nephrol. Dial. Transplant. 15, 301–304 (2000).
Batuman, V. The pathogenesis of acute kidney impairment in patients with multiple myeloma. Adv. Chronic Kidney Dis. 19, 282–286 (2012).
Dimopoulos, M. A. et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J. Clin. Oncol. 28, 4976–4984 (2010).
Dimopoulos, M. et al. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood 117, 4701–4705 (2011).
Kyle, R. A. & Rajkumar, S. V. Multiple myeloma. N. Engl. J. Med. 351, 1860–1873 (2004).
Hillengass, J. et al. Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma. J. Clin. Oncol. 28, 1606–1610 (2010).
Kastritis, E., Moulopoulos, L. A., Terpos, E., Koutoulidis, V. & Dimopoulos, M. A. The prognostic importance of the presence of more than one focal lesion in spine MRI of patients with asymptomatic (smoldering) multiple myeloma. Leukemia 28, 2402–2403 (2014).
Sonneveld, P. et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood 127, 2955–2962 (2016). This paper is a consensus approach to the treatment of high-risk multiple myeloma.
Kumar, S. et al. Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood 119, 2100–2105 (2012).
Hebraud, B. et al. Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience. Blood 125, 2095–2100 (2015).
Leiba, M. et al. Translocation t(11;14) in newly diagnosed patients with multiple myeloma: is it always favorable? Genes Chromosomes Cancer 55, 710–718 (2016).
Mikhael, J. R. et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin. Proc. 88, 360–376 (2013).
Chng, W. J. et al. IMWG consensus on risk stratification in multiple myeloma. Leukemia 28, 269–277 (2014).
Boyd, K. D. et al. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia 26, 349–355 (2012).
Greipp, P. R. et al. International Staging System for Multiple Myeloma. J. Clin. Oncol. 23, 3412–3420 (2005).
Palumbo, A. et al. Revised International Staging System for Multiple Myeloma: a report from International Myeloma Working Group. J. Clin. Oncol. 33, 2863–2869 (2015). This is a large multicentre cohort of patients and is currently the most relevant risk stratification system.
Sigurdardottir, E. E. et al. The role of diagnosis and clinical follow-up of monoclonal gammopathy of undetermined significance on survival in multiple myeloma. JAMA Oncol. 1, 168–174 (2015).
Bianchi, G. et al. Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications. Blood 116, 2019–2025 (2010).
Rajkumar, S. V. et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 106, 812–817 (2005).
Mateos, M. V. & San Miguel, J. V. Smoldering multiple myeloma. Hematol. Oncol. 33 (Suppl. 1), 33–37 (2015).
Mateos, M. V. et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N. Engl. J. Med. 369, 438–447 (2013).
Mateos, M. V. et al. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial. Lancet 17, 1127–1136 (2016).
Korde, N. et al. Treatment with carfilzomib–lenalidomide–dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma. JAMA Oncol. 1, 746–754 (2015).
Knudsen, L. M., Rasmussen, T., Jensen, L. & Johnsen, H. E. Reduced bone marrow stem cell pool and progenitor mobilisation in multiple myeloma after melphalan treatment. Med. Oncol. 16, 245–254 (1999).
Rajkumar, S. V. et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 11, 29–37 (2010).
Durie, B. G. et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 389, 519–527 (2017).
Cavo, M. et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 376, 2075–2085 (2010).
Kumar, S. et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood 119, 4375–4382 (2012).
Moreau, P., Mary, J. Y. & Attal, M. Bortezomib–thalidomide–dexamethasone versus bortezomib–cyclophosphamide–dexamethasone as induction therapy prior to autologous stem cell transplantation in multiple myeloma. Br. J. Haematol. 168, 605–606 (2015).
Facon, T. et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial. Lancet 370, 1209–1218 (2007).
Palumbo, A. et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367, 825–831 (2006).
San Miguel, J. F. et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N. Engl. J. Med. 359, 906–917 (2008).
Benboubker, L. et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N. Engl. J. Med. 371, 906–917 (2014).
Palumbo, A. et al. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood 118, 4519–4529 (2011).
Attal, M. et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais Myelome. N. Engl. J. Med. 335, 91–97 (1996). This is the first randomized trial to demonstrate the importance of ASCT.
Child, J. A. et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N. Engl. J. Med. 348, 1875–1883 (2003).
Palumbo, A. et al. Autologous transplantation and maintenance therapy in multiple myeloma. N. Engl. J. Med. 371, 895–905 (2014).
Attal, M. et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N. Engl. J. Med. 366, 1782–1791 (2012).
McCarthy, P. L. et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N. Engl. J. Med. 366, 1770–1781 (2012).
McCarthy, P. L. et al. A meta-analysis of overall survival in patients with multiple myeloma treated with lenalidomide maintenance after high-dose melphalan and autologous stem cell transplant. Haematologica 101, 2–3 (2016).
Kumar, A., Kharfan-Dabaja, M. A., Glasmacher, A. & Djulbegovic, B. Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis. J. Natl Cancer Inst. 101, 100–106 (2009).
Sonneveld, P. et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J. Clin. Oncol. 30, 2946–2955 (2012).
Kumar, S. et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 17, e328–e346 (2016). This is the current response assessment criteria for multiple myeloma.
Munshi, N. C. et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis. JAMA Oncol. 3, 28–35 (2017). This is the first large meta-analysis study to confirm the importance of MRD in multiple myeloma.
Palumbo, A. et al. Continuous therapy versus fixed duration of therapy in patients with newly diagnosed multiple myeloma. J. Clin. Oncol. 33, 3459–3466 (2015).
Kumar, S. K. et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter International Myeloma Working Group study. Leukemia 26, 149–157 (2012).
Gonsalves, W. I. et al. Clinical course and outcomes of patients with multiple myeloma who relapse after autologous stem cell therapy. Bone Marrow Transplant. 51, 1156–1158 (2016).
Soutar, R. et al. Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma. Br. J. Haematol. 124, 717–726 (2004).
Kumar, S. et al. Impact of early relapse after auto-SCT for multiple myeloma. Bone Marrow Transplant. 42, 413–420 (2008).
Terpos, E. et al. European Myeloma Network guidelines for the management of multiple myeloma-related complications. Haematologica 100, 1254–1266 (2015).
Berenson, J. et al. Balloon kyphoplasty versus non-surgical fracture management for treatment of painful vertebral body compression fractures in patients with cancer: a multicentre, randomised controlled trial. Lancet Oncol. 12, 225–235 (2011).
Leigh, B. R., Kurtts, T. A., Mack, C. F., Matzner, M. B. & Shimm, D. S. Radiation therapy for the palliation of multiple myeloma. Int. J. Radiat. Oncol. Biol. Phys. 25, 801–804 (1993).
Gay, F. & Palumbo, A. Management of disease- and treatment-related complications in patients with multiple myeloma. Med. Oncol. 27 (Suppl. 1), S43–S52 (2010).
Richardson, P. G. et al. Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia 26, 595–608 (2012).
Cella, D., Kallich, J., McDermott, A. & Xu, X. The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Ann. Oncol. 15, 979–986 (2004).
Snowden, J. A. et al. Guidelines for supportive care in multiple myeloma 2011. Br. J. Haematol. 154, 76–103 (2011).
Nucci, M. & Anaissie, E. Infections in patients with multiple myeloma. Semin. Hematol. 46, 277–288 (2009).
Eda, H., Santo, L., David Roodman, G. & Raje, N. Bone disease in multiple myeloma. Cancer Treat. Res. 169, 251–270 (2016).
Pallis, A. G. et al. EORTC workshop on clinical trial methodology in older individuals with a diagnosis of solid tumors. Ann. Oncol. 22, 1922–1926 (2011).
Stewart, A. K. et al. Health-related quality of life results from the open-label, randomized, phase III ASPIRE trial evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma. J. Clin. Oncol. 34, 3921–3930 (2016).
Lokhorst, H. M. et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N. Engl. J. Med. 373, 1207–1219 (2015).
Palumbo, A. et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N. Engl. J. Med. 375, 754–766 (2016).
Dimopoulos, M. A. et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N. Engl. J. Med. 375, 1319–1331 (2016).
Hu, J., Van Valckenborgh, E., Menu, E., De Bruyne, E. & Vanderkerken, K. Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models. Dis. Model. Mech. 5, 763–771 (2012).
Groen, R. W. et al. Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma. Blood 120, e9–e16 (2012).
Chesi, M. et al. Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. Blood 120, 376–385 (2012).
Sacco, A. et al. Cancer cell dissemination and homing to the bone marrow in a zebrafish model. Cancer Res. 76, 463–471 (2016).
Zhan, F. et al. The molecular classification of multiple myeloma. Blood 108, 2020–2028 (2006).
Broyl, A. et al. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood 116, 2543–2553 (2010).
Kuiper, R. et al. A gene expression signature for high-risk multiple myeloma. Leukemia 26, 2406–2413 (2012).
Shaughnessy, J. D. Jr et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 109, 2276–2284 (2007).
Otto, T. & Sicinski, P. Cell cycle proteins as promising targets in cancer therapy. Nat. Rev. Cancer 17, 93–115 (2017).
Manier, S. et al. Genomic complexity of multiple myeloma and its clinical implications. Nat. Rev. Clin. Oncol. 14, 100–113 (2017).
Bianchi, G. & Munshi, N. C. Pathogenesis beyond the cancer clone(s) in multiple myeloma. Blood 125, 3049–3058 (2015).
Guillerey, C., Nakamura, K., Vuckovic, S., Hill, G. R. & Smyth, M. J. Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies. Cell. Mol. Life Sci. 73, 1569–1589 (2016).
Zannettino, A. C. et al. Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. Cancer Res. 65, 1700–1709 (2005).
Dairaghi, D. J. et al. CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease. Blood 120, 1449–1457 (2012).
Hope, C. et al. TPL2 kinase regulates the inflammatory milieu of the myeloma niche. Blood 123, 3305–3315 (2014).
Hazlehurst, L. A., Damiano, J. S., Buyuksal, I., Pledger, W. J. & Dalton, W. S. Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene 19, 4319–4327 (2000).
Novak, A. J. et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood 103, 689–694 (2004).
Ilcus, C. et al. Immune checkpoint blockade: the role of PD-1–PD-L axis in lymphoid malignancies. Onco Targets Ther. 10, 2349–2363 (2017).
Attal, M. & Harousseau, J. L. Standard therapy versus autologous transplantation in multiple myeloma. Hematol. Oncol. Clin. North Am. 11, 133–146 (1997).
Gertz, M. A. et al. Impact of age and serum creatinine value on outcome after autologous blood stem cell transplantation for patients with multiple myeloma. Bone Marrow Transplant. 39, 605–611 (2007).
S.K.K. has served as a consultant for Takeda, Amgen, AbbVie, Merck, Janssen and Skyline Dx. K.C.A. is a member of the advisory board for Millennium Pharmaceuticals, Bristol-Myers Squibb and Gilead Sciences, and is a Scientific Founder of OncoPep and C4 Therapeutics. R.A.K. serves on the disease monitoring committees for Celgene, Bristol-Myers Squibb, Onyx Pharmaceuticals (Amgen) and Pharmacyclics. P.S. is an adviser for Amgen, Bristol-Myers Squibb, Celgene, Janssen, Takeda and Skyline Dx, and has received research support from Amgen, Celgene, Janssen and Takeda. F.G. serves as an adviser for Celgene, Takeda, Roche, Seattle Genetics and Amgen, and has received honoraria from Celgene, Janssen, Amgen, Bristol-Myers Squib and Takeda. M.-V.M. is a consultant for Amgen, Celgene, Janssen and Takeda, and has received speaker's fees from Janssen, Celgene, Amgen and Takeda. V.R. and M.v.D. declare no competing interests.
About this article
Cite this article
Kumar, S., Rajkumar, V., Kyle, R. et al. Multiple myeloma. Nat Rev Dis Primers 3, 17046 (2017). https://doi.org/10.1038/nrdp.2017.46
This article is cited by
Identification of clinical implications and potential prognostic models of chromatin regulator mutations in multiple myeloma
Clinical Epigenetics (2022)
Journal of Hematology & Oncology (2022)
CXCL13 chemokine is a novel player in multiple myeloma osteolytic microenvironment, M2 macrophage polarization, and tumor progression
Journal of Hematology & Oncology (2022)
Biomarker Research (2022)
Biomarker Research (2022)